|
|
阿立哌唑治疗帕利哌酮引起高泌乳素血症机制及研究进展
|
Abstract:
精神分裂症是一种致残率较高的慢性疾病。帕利哌酮是常用的抗精神病药物，高泌乳素血症是使用帕利哌酮时常见的副作用。在这种情况下，联合使用阿立哌唑可以有效降低泌乳素水平。因此，了解高泌乳素血症的产生机制、帕利哌酮导致高泌乳素血症的机制以及阿立哌唑降低泌乳素水平的作用机制，对于改善患者的生存质量尤为重要。本文综述了阿立哌唑治疗帕利哌酮引起的高泌乳素血症的机制，旨在探索有效的精神专科治疗方案。
Schizophrenia is a chronic disease with a high morbidity rate. Paliperidone is a commonly used antipsychotic drug; however, hyperprolactinemia is a common side effect of paliperidone. In this setting, coadministration with aripiprazole may be effective in reducing prolactin levels. Therefore, understanding the mechanism of hyperprolactinemia, the mechanism of paliperidone causing hyperprolactinemia, and the mechanism of aripiprazole reducing prolactin levels is particularly important to improve the quality of life of patients. This article reviews the mechanism of aripiprazole in the treatment of paliperidone-induced hyperprolactinemia, aiming to explore effective psychiatric treatment options.
| [1] | Dawn, I.V. and Subramanyeshwar, R. (2023) The Epidemiology and Global Burden of Schizophrenia. The Journal of Clinical Psychiatry, 84, MS21078COM5. |
| [2] | Piparva, K.G., Buch, J.G. and Chandrani, K.V. (2011) Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPD. Indian Journal of Psychological Medicine, 33, 153-157. https://doi.org/10.4103/0253-7176.92067 |
| [3] | Halbreich, U. and Kahn, L.S. (2003) Hyperprolactinemia and Schizophrenia: Mechanisms and Clinical Aspects. Journal of Psychiatric Practice, 9, 344-353. https://doi.org/10.1097/00131746-200309000-00003 |
| [4] | Austen, Y. and Mujeeb, U.S. (2020) Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series. The Primary Care Companion for CNS Disorders, 22, 19br02536. |
| [5] | 中国神经科学学会精神病学基础与临床分会精神分裂症临床研究联盟. 抗精神病药所致高泌乳素血症干预对策的专家共识[J]. 中华精神科杂志, 2021, 54(3): 163-169. |
| [6] | Nicholas, A.T. and Anne, K. (2015) Hyperprolactinemia. JAMA, 314, 1742-1743. |
| [7] | Schlechte, J.A. (2003) Prolactinoma. New England Journal of Medicine, 349, 2035-2041. https://doi.org/10.1056/nejmcp025334 |
| [8] | Begon, E. and Bernard, V. (2022) Prolactin and Its Receptor: From Animal Models to Pituitary Pathophysiology. Biologie Aujourd’hui, 216, 105-110. https://doi.org/10.1051/jbio/2022019 |
| [9] | Fitzgerald, P. and Dinan, T.G. (2008) Prolactin and Dopamine: What Is the Connection? A Review Article. Journal of Psychopharmacology, 22, 12-19. https://doi.org/10.1177/0269216307087148 |
| [10] | Kirsch, P., Kunadia, J., Shah, S. and Agrawal, N. (2022) Metabolic Effects of Prolactin and the Role of Dopamine Agonists: A Review. Frontiers in Endocrinology, 13, Article 1002320. https://doi.org/10.3389/fendo.2022.1002320 |
| [11] | Lv, C., Mo, C., Liu, H., Wu, C., Li, Z., Li, J., et al. (2018) Dopamine D2-Like Receptors (DRD2 and DRD4) in Chickens: Tissue Distribution, Functional Analysis, and Their Involvement in Dopamine Inhibition of Pituitary Prolactin Expression. Gene, 651, 33-43. https://doi.org/10.1016/j.gene.2018.01.087 |
| [12] | Ángel, L.M., Buch, B., López, M.J., et al. (2022) Hormonal Alterations Due to Antipsychotic-Related Hyperprolactinemia. European Psychiatry, 65, S782. |
| [13] | Katharina, W. (2021) Hyperprolactinemia in Women. Journal für Gynäkologische Endokrinologie/Österreich, 31, 102-105. https://doi.org/10.1007/s41974-021-00195-7 |
| [14] | Maggi, M., Buvat, J., Corona, G., Guay, A. and Torres, L.O. (2013) Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA). The Journal of Sexual Medicine, 10, 661-677. https://doi.org/10.1111/j.1743-6109.2012.02735.x |
| [15] | Yun, S.J., Sang, H., Park, S.Y. and Chin, S.O. (2024) Effect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis. International Journal of Molecular Sciences, 25, Article 1474. https://doi.org/10.3390/ijms25031474 |
| [16] | Katsuya, T., Katsumi, S. and Akio, S. (2019) Paliperidone/Risperidone. Reactions Weekly, 1466, 34. |
| [17] | Minwalla, H.D., Wrzesinski, P., Desforges, A., Caskey, J., Wagner, B., Ingraffia, P., et al. (2021) Paliperidone to Treat Psychotic Disorders. Neurology International, 13, 343-358. https://doi.org/10.3390/neurolint13030035 |
| [18] | Montejo, Á.L., Arango, C., Bernardo, M., Carrasco, J.L., Crespo-Facorro, B., Cruz, J.J., et al. (2017) Multidisciplinary Consensus on the Therapeutic Recommendations for Iatrogenic Hyperprolactinemia Secondary to Antipsychotics. Frontiers in Neuroendocrinology, 45, 25-34. https://doi.org/10.1016/j.yfrne.2017.02.003 |
| [19] | Besnard, I., Auclair, V., Callery, G., Gabriel-Bordenave, C. and Roberge, C. (2014) Antipsychotic-Drug-Induced Hyperprolactinemia: Physiopathology, Clinical Features and Guidance. L’Encéphale, 40, 86-94. https://doi.org/10.1016/j.encep.2012.03.002 |
| [20] | Duval, F., Guillon, M., Mokrani, M., Crocq, M. and Garcia Duarte, F. (2008) Relationship between Prolactin Secretion, and Plasma Risperidone and 9-Hydroxyrisperidone Concentrations in Adolescents with Schizophreniform Disorder. Psychoneuroendocrinology, 33, 255-259. https://doi.org/10.1016/j.psyneuen.2007.10.010 |
| [21] | Einarson, T.R., Hemels, M.E., Nuamah, I., Gopal, S., Coppola, D. and Hough, D. (2012) An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. Annals of Pharmacotherapy, 46, 1322-1330. https://doi.org/10.1345/aph.1r123 |
| [22] | 金圭星, 王岚, 于鲁璐, 等. 不同剂型帕利哌酮对精神分裂症患者泌乳素水平影响的研究[C]//中华医学会第十一次全国精神医学学术会议暨第三届亚洲神经精神药理学术会议论文集. 2013: 149-150. |
| [23] | Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T. and McQuade, R.D. (2021) Discovery Research and Development History of the Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpiprazole. Neuropsychopharmacology Reports, 41, 134-143. https://doi.org/10.1002/npr2.12180 |
| [24] | Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., et al. (2003) Aripiprazole, an Antipsychotic with a Novel Mechanism of Action, and Risperidone vs Placebo in Patients with Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry, 60, 681-690. https://doi.org/10.1001/archpsyc.60.7.681 |
| [25] | Soria-Chacartegui, P., Villapalos-García, G., Zubiaur, P., Abad-Santos, F. and Koller, D. (2021) Genetic Polymorphisms Associated with the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in Pharmacology, 12, Article 711940. https://doi.org/10.3389/fphar.2021.711940 |
| [26] | Bernagie, C., Danckaerts, M., Wampers, M. and De Hert, M. (2016) Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs, 30, 807-818. https://doi.org/10.1007/s40263-016-0367-y |
| [27] | Wang, X., Mei, D., Lu, Z., Zhang, Y., Sun, Y., Lu, T., et al. (2023) Genome-wide Association Study Identified Six Loci Associated with Adverse Drug Reactions to Aripiprazole in Schizophrenia Patients. Schizophrenia, 9, Article No. 44. https://doi.org/10.1038/s41537-023-00369-6 |
| [28] | Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L., Sibley, D.R., et al. (2003) Aripiprazole, a Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology, 28, 1400-1411. https://doi.org/10.1038/sj.npp.1300203 |
| [29] | Ma, B., Zhao, W., Fan, H., Yun, Y., Qi, S., An, H., et al. (2023) Relationship between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 33, 27-33. https://doi.org/10.1089/cap.2022.0068 |
| [30] | Tasaki, M., Yasui-Furukori, N., Kubo, K., Yokoyama, S., Shinozaki, M., Sugawara, N., et al. (2021) Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients with Schizophrenia. Therapeutic Drug Monitoring, 43, 589-592. https://doi.org/10.1097/ftd.0000000000000843 |
| [31] | Joseph, S.P. (2016) Aripiprazole-Induced Hyperprolactinemia in a Young Female with Delusional Disorder. Indian Journal of Psychological Medicine, 38, 260-262. https://doi.org/10.4103/0253-7176.183082 |
| [32] | Kelly, D.L., Wehring, H.J., Earl, A.K., Sullivan, K.M., Dickerson, F.B., Feldman, S., et al. (2013) Treating Symptomatic Hyperprolactinemia in Women with Schizophrenia: Presentation of the Ongoing DAAMSEL Clinical Trial (Dopamine Partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated Prolactin). BMC Psychiatry, 13, Article No. 214. https://doi.org/10.1186/1471-244x-13-214 |
| [33] | Snellen, M., Power, J., Blankley, G. and Galbally, M. (2016) Pharmacological Lactation Suppression with D2 Receptor Agonists and Risk of Postpartum Psychosis: A Systematic Review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 56, 336-340. https://doi.org/10.1111/ajo.12479 |
| [34] | Labad, J., Montalvo, I., González-Rodríguez, A., García-Rizo, C., Crespo-Facorro, B., Monreal, J.A., et al. (2020) Data of a Meta-Analysis on Pharmacological Treatment Strategies for Lowering Prolactin in People with a Psychotic Disorder and Hyperprolactinaemia. Data in Brief, 31, Article ID: 105904. https://doi.org/10.1016/j.dib.2020.105904 |
| [35] | 黄锦, 朱丞. 帕利哌酮缓释片联合阿立哌唑对精神分裂症精神病性症状、认知功能和催乳素的影响[J]. 中华全科医学, 2022, 20(10): 1688-1690, 1791. |
| [36] | 王飞, 车清磊, 王蕊, 等. 阿立哌唑对部分抗精神病药物所致高泌乳素血症疗效对比[J]. 中外医疗, 2022, 41(16): 67-70. |
| [37] | 汪毅, 甘明远, 刘华清, 等. 帕利哌酮缓释片与阿立哌唑治疗青少年首发精神分裂症的疗效和催乳素变化[J]. 中国心理卫生杂志, 2019, 33(8): 592-597. |
| [38] | 朱峰, 梅其一, 沈建红, 等. 阿立哌唑对帕利哌酮引起的高泌乳素水平的影响[C]//中华医学会第十次全国精神医学学术会议论文集. 2012: 140-141. |
| [39] | Jiang, Q., Li, T., Zhao, L., Sun, Y., Mao, Z., Xing, Y., et al. (2024) Treatment of Antipsychotic-Induced Hyperprolactinemia: An Umbrella Review of Systematic Reviews and Meta-Analyses. Frontiers in Psychiatry, 15, Article 1337274. https://doi.org/10.3389/fpsyt.2024.1337274 |
| [40] | Sá Esteves, P., Mota, D., Cerejeira, J., Mendes, F., et al. (2015) Low Doses of Adjunctive Aripiprazole as Treatment for Antipsychotic-Induced Hyperprolactinemia: A Literature Review. European Psychiatry, 30, 393. |
| [41] | 陈景旭, 王宁, 卞清涛, 等. 阿立哌唑对利培酮所致高催乳素血症的疗效[J]. 临床精神医学杂志, 2009, 19(2): 127-129. |
| [42] | Qiao, Y., Yang, F.Z., Li, C.B., et al. (2016) Add-On Effects of a Low-Dose Aripiprazole in Resolving Hyperprolactinemia Induced by Risperidone or Paliperidone. Psychiatry Research, 237, 83-89. |
| [43] | Meng, M.L., Li, W., Zhang, S.W., et al. (2015) Using Aripiprazole to Reduce Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Currently Available Randomized Controlled Trials. Shanghai Arch Psychiatry, 27, 4-17. |
| [44] | Krøigaard, S.M., Clemmensen, L., Tarp, S. and Pagsberg, A.K. (2022) A Meta-Analysis of Antipsychotic-Induced Hypo-and Hyperprolactinemia in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 32, 374-389. https://doi.org/10.1089/cap.2021.0140 |
| [45] | Li, X., Tang, Y. and Wang, C. (2013) Adjunctive Aripiprazole versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials. PLOS ONE, 8, e70179. https://doi.org/10.1371/journal.pone.0070179 |
| [46] | Chen, J., Su, Y., Bian, Q., Wei, L., Zhang, R., Liu, Y., et al. (2015) Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study. Psychoneuroendocrinology, 58, 130-140. https://doi.org/10.1016/j.psyneuen.2015.04.011 |
